Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2006-12-05
2006-12-05
Rawlings, Stephen L. (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S350000, C530S387300, C530S387700, C530S388800, C536S023400
Reexamination Certificate
active
07144991
ABSTRACT:
The present invention provides vectors for expressing genomic streptavidin fusion cassettes. In the various embodiments, fusion proteins produced from these vectors are provided. In particular embodiments, fusion proteins comprising a single chain antibody and genomic streptavidin are provided as are vectors encoding the same. Also provided, are methods of using the fusion proteins of the present invention, and in particular, the use of scFvSA fusion proteins as diagnostic markers or as a cell specific targeting agents.
REFERENCES:
patent: 4839293 (1989-06-01), Cantor et al.
patent: 4867973 (1989-09-01), Goers et al.
patent: 4975369 (1990-12-01), Beavers et al.
patent: 5169939 (1992-12-01), Gefter et al.
patent: 5272254 (1993-12-01), Meade et al.
patent: 5328985 (1994-07-01), Sano et al.
patent: 5334532 (1994-08-01), Tackney et al.
patent: 5395609 (1995-03-01), Stuttle
patent: 5530101 (1996-06-01), Queen et al.
patent: 5630996 (1997-05-01), Reno et al.
patent: 5696237 (1997-12-01), FitzGerald et al.
patent: 5837816 (1998-11-01), Ciardelli et al.
patent: 5863745 (1999-01-01), Fitzgerald et al.
patent: 6156321 (2000-12-01), Thorpe et al.
patent: 6204023 (2001-03-01), Robinson et al.
patent: 6451995 (2002-09-01), Cheung et al.
patent: 682 040 (1995-11-01), None
patent: 496 074 (1996-11-01), None
patent: WO 86/02077 (1986-04-01), None
patent: WO 87/05026 (1987-08-01), None
patent: WO 93/24631 (1993-12-01), None
patent: WO 95/15770 (1995-06-01), None
patent: WO 95/25167 (1995-09-01), None
patent: WO 97/18314 (1997-05-01), None
patent: WO 97/19957 (1997-06-01), None
patent: WO 97/34634 (1997-09-01), None
patent: WO 98/50432 (1998-11-01), None
Critchfield GC. Disease Markers. 1999; 15: 108-11.
Tockman MS, et al. Cancer Res. 1992; 52 (Suppl.): 2711s-2718s.
Ward AM. Developmental Oncol. 1985; 21: 90-106.
Skolnick J, et al. Trends Biotechnol 2000 Jan; 18 (1): 34-9.
Rudikoff S, et al. Proc Natl Acad Sci USA. Mar. 1982; 79; 1979-83.
Sidransky D. Science. Nov. 7, 1997; 278 (5340): 1054-9.
Kashmiri SV, et al. Hybridoma. Oct. 1995; 14 (5): 461-73.
Sharkey RM, et al. Bioconj Chem. Jul.-Aug. 1997; 8 (4): 595-604.
Epivatanos A, et al. Oral Dis. Mar. 2000; 6 (2): 112-7.
Karacay H, et al. Bioconjug Chem. Jul.-Aug. 1997; 8 (4): 585-94.
Bowie et al., “Deciphering the message in protein sequences: tolerance to amino acid substitutions,”Science247(4948):1306-1310, Mar. 16, 1990.
Burgess et al., “Possible dissociation of the heparin-binding and mitogenic activities of heparin-binding (acidic fibroblast) growth factor-1 from its receptor-binding activities by site-directed mutagenesis of a single lysine residue,”J. Cell Biol.111:2129-2138, Nov. 1990.
Lazar et al., “Transforming growth factor alpha: mutation of aspartic acid 47 and leucine 48 results in different biological activities,”Mol. Cell Biol.8(3):1247-1252, Mar. 1988.
Alfthan et al., “Properties of a Single-Chain Antibody Containing Different Linker Peptides,”Protein Eng, 8(7):725-731, 1995.
Anderson et al., “A Primatized Mab to human CD4 causes receptor modulation, without marked reduction in CD4+T cells in chimpanzees,”Clinical Immunology and Immunopathology84: 73-84, 1997.
Argaraña et al., “Molecular Cloning and Nucleotide Sequence of the Streptavidin Gene,”Nucl. Acids Res.14(4):1871-1882, 1986.
Axworthy et al., “Antibody pretargeting for radioimmunotherapy: a three-step approach in tumored nude mice,”J. Nucl. Med.33 (5 SUPPL.): 880, 1992.
Axworthy et al., “Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligle toxicity,”Proc. Natl. Acad. Sci. USA97: 1802-1807, 2000.
Better, “T-Cell-Targeted Immunofusion Proteins FromE. Coli,” Annals N. Y. Acad. Sci.782:544-54, 1996.
Bird et al., “Single-Chain Antigen-Binding Proteins,”Science242:423-426, 1988.
Bodey et al., “Failure of cancer vaccines: the significant limitations of this approach to immunotherapy,”Anticancer Research20(4) : 2665-2676, Jul./Aug. 2000.
Boleti et al., “Construction, Expression and Characterization of a Single-Chain Anti-Tumour Antibody (scFv)-IL-2 Fusion Protein,”Annals Oncol.6:945-947, 1995.
Buchegger et al., “Radiolabeled Chimeric Anit-CEA Monoclonal Antibody Compared with the original Mouse Monoclonal Antibody for Surgically Treated Colorectal Carcinoma,”The Journal of Nuclear Medicine36(3):420-429, 1995.
Chilkoti et al., “Engineered chimeric streptavidin tetramers as novel tools for bioseparations and drug delivery,”Bio/Technology13: 1198-1204, 1995.
Curti, B.D., “Physical barriers to drug delivery tumors,”Critical Reviews in Hematology/Oncology14: 29-39, 1993.
Darveau et al., “Expression of Antibody Fragments inEscherichia coli,” J. Clin. Immunoassay15(1):25-29, 1992.
DeNardo et al., “Strategies for developing effective radioimmunotherapy for solid tumors,”Clinical Cancer Research5: 3219s-3223s, 1999.
Desplancq et al., “Multimerization Behaviour of Single Chain Fv Variants for the Tumour-Binding Antibody B72.3,”Protein Eng.7(8):1027-1033, 1994.
Dübel et al., “Bifunctional and Multimeric Complexes of Streptavidin Fused to Single-Chain Antibodies (scFv),”J. Immunol. Meth.178:201-209, 1995.
Fell et al., “Genetic Construction and Characterization of a Fusion Protein Consisting of a Chimeric F(ab') with Specificity for Carcinomas and Human IL-2,”The Journal of Immunology146(7):2446-2452, 1991.
Filpula et al., “Engineering of Immunoglobulin Fc and Single-Chain Fv Proteins inEscherichia coli,” Antibody Expression and Engineering, ACS Symposium Series No. 604, Chap. 6, pp. 71-82, American Chemical Society: Washington, D.C., 1995.
Gallizia et al., “Production of a Soluble and Functional Recombinant Streptavidin inEscherichia coli,” Protein Expr. Purif.14:192-196, 1998.
Goodwin and Hnatowich, “Tumor Imaging with Indium-Labeled Biotin. Letter to the Editor and Reply,”The Journal of Nuclear Medicine32(4):750-751, 1991.
Goodwin et al., “Pharmacokinetics of Biotin-Chelate Conjugates for Pretargeted Avidin-Biotin Immunoscintigraphy,”The Journal of Nuclear Medicine33(Suppl. 5):p. 880, Abstract No. 232, 1992.
Goshorn et al., “Genetic Construction, Expression, and Characterization of a Single-Chain Anti-Carcinoma Antibody Fused to β-Lactamase,”Cancer Res.53:2123-2127, 1993.
Gura, T., “Systems for identifying drugs are often faulty,”Science278: 1041-1042, 1997.
Hand et al., “Comparitive Biological Properties of a Recombinant Chimeric Anti-Carcinoma mAb and a Recombinant Aglycosylated Variant,”Cancer Immunology Immunotherapy35:165-174, 1992.
Hnatawich et al., “Investigations of avidin and biotin for imaging applications,”Journal of Nuclear Medicine28: 1294-1302, 1987.
Huston et al., “Antigen Recognition and Targeted Delivery by the Single-Chain Fv,”Cell Biophys.22:189-224, 1993.
Huston et al., “Protein Engineering of Antibody Binding Sites: Recovery of Specific Activity in an Anti-Digoxin Single-Chain Fv Analogue Produced inEscherichia coli,” Proc. Natl. Acad. Sci.85:5879-5883, 1988.
Huston et al., “Protein Engineering of Single-Chain Fv Analogs and Fusion Proteins,”meth. Enzymol.203:46-89, 1991.
Jain, R.K., “Barriers to drug delivery in solid tumors,”Scientific American271: 58-65, 1994.
Kalofonos et al., “Imaging of Tumor in Patients with Indium-111-Labeled Biotin and Streptavidin-Conjugated Antibodies: Preliminary Communication,”J. Nucl. Med.31:1791-1796, 1990.
Karp et al., “Identification of Biotinylated Molecules Using a Baculovirus-Expressed Luciferase-Streptavidin Fusion Protein,”Biotechniques20:452-459, 1996.
Kerschbaurner et al., “Single-Chain Fv Fusion Proteins Suitable as Coating and Detecting Reagents ina Double Antibody Sandwich Enzyme-Linked Immunosorb
Goshorn Stephen Charles
Graves Scott Stoll
Lin Yukang
Reno John M.
Sanderson James Allen
Aletheon Pharmaceuticals, Inc.
Rawlings Stephen L.
Seed IP Law Group PLLC
LandOfFree
Streptavidin expressed gene fusions and methods of use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Streptavidin expressed gene fusions and methods of use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Streptavidin expressed gene fusions and methods of use thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3685705